Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

Core Insights - Vanda Pharmaceuticals Inc. is participating in the American Academy of Neurology Annual Meeting, presenting a novel therapeutic approach for Charcot-Marie-Tooth disease type 2S (CMT2S) [1][2] - The presentation will showcase VCA-894A, a personalized medicine treatment tailored to a specific genetic mutation, demonstrating significant improvements in neuromuscular function [1][2] - VCA-894A has received orphan designation from the FDA and is expected to be administered to the patient for whom it was developed, highlighting its potential in addressing unmet medical needs [2] Presentation Details - The presentation titled "Translating IGHMBP2 Variants with a CMT2S Patient-specific Organ-on-a-chip Model: Personalized Medicine ASO-based Therapeutic Rescue" will take place on April 9, 2025 [1] - The poster session will include novel unpublished data on conduction velocity in addition to previously published findings [3] Company Overview - Vanda Pharmaceuticals is focused on developing innovative therapies to meet high unmet medical needs and improve patient lives [5]